Anti-anemic Activity of Aqueous Root Bark Extract of Morinda lucida Benth against Phenylhydrazine-induced Hemolytic Anemia in Wistar Rats

Aims: Evaluate the anti-anemic potential of aqueous root bark extract of Morinda lucida against induced hemolytic anemia in Wistar rats in addition to its total phenol content and its acute toxicity. Study Design: Experimental Design. Place and Duration of Study: Laboratory of Biology and Health, Training and Research Unit Biosciences, Félix Houphouët-Boigny University of Abidjan, June 2024 to September 2024. Methodology: Total phenol content of aqueous root bark extract of Morinda lucida was determined using Folin-Ciocalteu reagent. The acute toxicity test was performed according to OECD guideline no. 425. Anemia was induced in Wistar rats by intraperitoneal administration of phenylhydrazine at 40 mg/Kg bw for two days. The rats were orally treated during 21 days with 100 and 200 mg/kg bw of Morinda lucida extract and Ranferon® (anti-anemic drug) at 50 mg/kg bw. Blood was collected from all rats before and after induction of anemia, and then weekly during the treatment period to monitor changes in hematological parameters such as hemoglobin level, red blood cell count, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration. Results: The results show that the aqueous root bark extract of Morinda lucida contains phenolic compounds, estimated at 0.169 ± 0.015 mg gallic acid equivalent/g extract, and has low toxicity. In anti-anemic test, phenylhydrazine caused a significant reduction in hemoglobin level in rats, from 13.33 to 8.33 g/dL, with a disturbance in the other hematological parameters. After 15 days of treatment, hemoglobin levels significantly increased in rats treated with M. lucida extract at 100 mg/kg (13.27±0.26 g/dL) and Ranferon® (12.93±0.145 g/dL), comparable to normal controls (13.17±0.03 g/dL). There were also improvements in the other hematological parameters after two to three weeks treatment. Conclusion: These results show that Morinda lucida is effective in repairing phenylhydrazine-induced erythrocyte damage and highlight its anti-anemic potential.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Research International
Published
2025-04-07
DOI
https://doi.org/10.9734/jpri/2025/v37i47682
Primary Topic
Morinda citrifolia extract uses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anti-anemic Activity of Aqueous Root Bark Extract of Morinda lucida Benth against Phenylhydrazine-induced Hemolytic Anemia in Wistar Rats

Jean David N’Guessan, Kouassi Konan Armand Marcelin, Samuel Mong’are, Duni Sawadogo et al.
Journal of Pharmaceutical Research International
Morinda citrifolia extract uses
article

Anti-anemic Activity of Aqueous Root Bark Extract of Morinda lucida Benth against Phenylhydrazine-induced Hemolytic Anemia in Wistar Rats

Jean David N’Guessan, Kouassi Konan Armand Marcelin, Samuel Mong’are, Duni Sawadogo, Djaman Allico Joseph, Kolia Kouamé Innocent
article en

Abstract

Aims: Evaluate the anti-anemic potential of aqueous root bark extract of Morinda lucida against induced hemolytic anemia in Wistar rats in addition to its total phenol content and its acute toxicity. Study Design: Experimental Design. Place and Duration of Study: Laboratory of Biology and Health, Training and Research Unit Biosciences, Félix Houphouët-Boigny University of Abidjan, June 2024 to September 2024. Methodology: Total phenol content of aqueous root bark extract of Morinda lucida was determined using Folin-Ciocalteu reagent. The acute toxicity test was performed according to OECD guideline no. 425. Anemia was induced in Wistar rats by intraperitoneal administration of phenylhydrazine at 40 mg/Kg bw for two days. The rats were orally treated during 21 days with 100 and 200 mg/kg bw of Morinda lucida extract and Ranferon® (anti-anemic drug) at 50 mg/kg bw. Blood was collected from all rats before and after induction of anemia, and then weekly during the treatment period to monitor changes in hematological parameters such as hemoglobin level, red blood cell count, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration. Results: The results show that the aqueous root bark extract of Morinda lucida contains phenolic compounds, estimated at 0.169 ± 0.015 mg gallic acid equivalent/g extract, and has low toxicity. In anti-anemic test, phenylhydrazine caused a significant reduction in hemoglobin level in rats, from 13.33 to 8.33 g/dL, with a disturbance in the other hematological parameters. After 15 days of treatment, hemoglobin levels significantly increased in rats treated with M. lucida extract at 100 mg/kg (13.27±0.26 g/dL) and Ranferon® (12.93±0.145 g/dL), comparable to normal controls (13.17±0.03 g/dL). There were also improvements in the other hematological parameters after two to three weeks treatment. Conclusion: These results show that Morinda lucida is effective in repairing phenylhydrazine-induced erythrocyte damage and highlight its anti-anemic potential.

Journal of Pharmaceutical Research InternationalVol. 37(4)
Centre Hospitalier Universitaire de Yopougon (CI), Université Félix Houphouët-Boigny (CI)
Openalex Percentile: Top 90%
Morinda citrifolia extract uses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.